Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.29
- Piotroski Score 5.00
- Grade Outperform
- Symbol (BNR)
- Company Burning Rock Biotech Limited
- Price $5.38
- Changes Percentage (15.24%)
- Change $0.71
- Day Low $4.80
- Day High $5.40
- Year High $9.99
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/21/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$8.11
- Trailing P/E Ratio -0.96
- Forward P/E Ratio -0.96
- P/E Growth -0.96
- Net Income $-653,689,000
Income Statement
Quarterly
Annual
Latest News of BNR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Brenntag (ETR:BNR) investors are sitting on a loss of 19% if they invested three years ago
Investors aim to beat market returns by picking stocks, but Brenntag SE (ETR:BNR) has underperformed, with a 25% drop in share price in the last three years. Despite growing EPS by 5.2% annually, reve...
By Yahoo! Finance | 5 days ago -
In the wake of Brenntag SE's (ETR:BNR) latest €364m market cap drop, institutional owners may be forced to take severe actions
Analyzing ownership structure and analyst forecasts can provide valuable insights into a company's performance. Institutions dominate Brenntag SE ownership, influencing stock movements. Insider owners...
By Yahoo! Finance | 1 month ago -
Should You Investigate Brenntag SE (ETR:BNR) At €64.28?
Brenntag SE's stock price remained stable in the past weeks, indicating it is trading around fair value compared to industry peers. The company's positive outlook suggests potential growth in earnings...
By Yahoo! Finance | 2 months ago
